Healthcare Industry News: ABRAXANE
News Release - September 6, 2006
Abraxis Oncology Appoints Vice President Global Drug Development
Dr. Jose Iglesias to Lead Clinical Development in Canada, Central and South America, and Asia PacificTORONTO, Sept. 6 (Healthcare Sales & Marketing Network) - Abraxis Oncology, a division of Abraxis BioScience Inc (NASDAQ: ABBI ), today announced the appointment of Dr. Jose Iglesias as vice president of global clinical development and medical affairs. In this position, Dr. Iglesias will assume leadership responsibility for ABRAXANE(TM) for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound (nab) paclitaxel) and new molecule clinical research in Canada, Central and South America, and Asia Pacific. He will also manage the medical affairs activities of Abraxis Oncology in Canada.
Dr. Iglesias brings to this position more than 16-years experience in the global development of innovative pharmaceutical oncology products. Previous to joining Abraxis Oncology, Dr. Iglesias held several key global medical positions with Amgen Canada Inc. as well as Eli Lilly and Company in both Canada and Australia.
Dr. Iglesias holds a medical degree from Montevideo School of Medicine (University of the Republic, Uruguay). He also received additional medical research training at Duke University, University of Toronto in Canada and The Weizmann Institute of Science (Israel).
Dr. Iglesias will be based at Abraxis Oncology's Richmond Hill, Ontario office for all Canadian and International responsibilities. In his Canadian capacity, he will report directly to Lyndal Walker, vice president and managing director of Abraxis Oncology in Canada.
About ABRAXANE
ABRAXANETM(TM) for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound (nab) paclitaxel) received approval in June 2006 from the Therapeutic Products Directorate of Health Canada under a Notice of Compliance for the treatment of metastatic breast cancer in Canada. Canada is the first major commercial market to grant an approval for ABRAXANE that includes first-line treatment of metastatic breast cancer. The U.S. Food and Drug Administration approved ABRAXANE in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. For the full prescribing information for ABRAXANE please visit www.ABRAXANE.com.
About Abraxis Oncology
Abraxis Oncology, a wholly-owned division of Abraxis BioScience Inc., is devoted to the global development and commercialization of next-generation cancer therapies. The Canadian affiliate of Abraxis Oncology is located in Richmond Hill, Ontario. For more information about the division and its products, please visit www.abraxisoncology.com.
About Abraxis BioScience Inc.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nabTM platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(TM), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ National Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.
Source: Abraxis Oncology
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.